A Drug for Down Syndrome

Join Our Community of Science Lovers!

Scientists may have finally found a drug candidate for reducing the mental retardation caused by Down syndrome. After as little as two weeks on the drug, mice with a genetic impairment similar to the syndrome performed as well as normal animals did on learning tests.

The learning and memory problems characteristic of Down syndrome may occur because its sufferers’ brain cells are unable to form new synaptic connections with neighboring neurons. This inhibition could be the result of overactive GABAA receptors—tiny ion channels on neurons. The drug the researchers tested, pentylenetetrazole (PTZ), interferes with the GABAA receptors, allowing new synapses to be formed at a normal rate.

For two to four weeks, researchers gave low doses of PTZ to mice bred to have an extra copy of one of their chromosomes. As in Down syndrome, this genetic anomaly causes malformed facial bones and learning problems. Immediately after treatment with PTZ, the animals’ scores on two memory tests—for recognizing objects they had seen before or remembering how they last entered a maze—were on par with normal mice. Two months later the altered mice still did much better than they would have done otherwise.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


The treatment “is allowing the normal properties of neurons to work,” says Stanford University neurobiologist Craig Garner, whose group performed the experiments. “This slowly, over time, leads to an improved circuit.”

Although the study results are hugely promising, there is a catch: PTZ, formerly used to treat psychiatric disorders, was taken off the market 25 years ago after being found to be ineffective and to cause dangerous seizures in some people. The dose used in the current study was much smaller than the dose that provoked seizures, however, so the researchers believe there is a good possibility that the drug can be used safely.

JR Minkel was a news reporter for Scientific American.

More by JR Minkel
SA Mind Vol 18 Issue 3This article was published with the title “A Drug for Down Syndrome” in SA Mind Vol. 18 No. 3 (), p. 12
doi:10.1038/scientificamericanmind0607-12a

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American

Subscribe